Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
African potato refers to the tuberous rootstock (corm) of the medicinal plant *Hypoxis hemerocallidea* (and related species such as *Hypoxis obtusa*), which is native to Southern Africa. It is widely utilized in traditional African medicine as an immunostimulant, particularly for managing HIV/AIDS, cancer, benign prostatic hyperplasia (BPH), and various inflammatory conditions. The primary bioactive component is the norlignan diglucoside **hypoxoside**, which is hydrolyzed by gut bacteria into its aglycone form, **rooperol**, a potent catechol-containing antioxidant. Clinical research has primarily focused on its pharmacological interactions with conventional therapies; for instance, trials have evaluated its effect on the pharmacokinetics of antiretroviral drugs like lopinavir/ritonavir and efavirenz. While in vitro data suggest it may inhibit various Cytochrome P450 enzymes and P-glycoprotein, clinical studies have generally found short-term use to be safe without significant drug-drug interactions in HIV patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on African potato.